Close Menu

SAIC-Frederick

The company will develop the cancer-targeted antibodies for SAIC-Frederick under an NCI proteomics initiative.

The new building will house a wide range of advanced research and development technologies — from biopharmaceutical development and manufacturing to genomics and nanotechnology — that ATPI partners can access by collaborating with NCI.

According to the solicitation, caBIG is seeking a contractor who can "maintain and enhance all components of caB2B in terms of functionality and usability along with maintainability, security, and performance through focused refactoring."

The NCI contractor will use Roche's sequence capture technology and FLX sequencer on cancer genomics tests.

Pages

A Minnesota toddler given a gene therapy to treat her spinal muscular atrophy is now walking, according to Newsweek.

NBC Bay Area reports a California lab has been certified to conduct forensic mitochondrial DNA sequencing.

The New York Times reports on how environmental DNA sampling could monitor endangered species.

In Cell this week: proteomic, genomic, and transcriptomic analysis of endometrial cancer; deep neural network learning-based approach to antibiotic discovery; and more.